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ABSTRACT
Genomic characterization of medulloblastoma has improved molecular risk 
classification but struggles to define functional biological processes, particularly for 
the most aggressive subgroups. We present here a novel proteomic approach to this 
problem using a reference library of stable isotope labeled medulloblastoma-specific 
proteins as a spike-in standard for accurate quantification of the tumor proteome. 
Utilizing high-resolution mass spectrometry, we quantified the tumor proteome of 
group 3 medulloblastoma cells and demonstrate that high-risk MYC amplified tumors 
can be segregated based on protein expression patterns. We cross-validated the 
differentially expressed protein candidates using an independent transcriptomic 
data set and further confirmed them in a separate cohort of medulloblastoma tissue 
samples to identify the most robust proteogenomic differences. Interestingly, highly 
expressed proteins associated with MYC-amplified tumors were significantly related 
to glycolytic metabolic pathways via alternative splicing of pyruvate kinase (PKM) by 
heterogeneous ribonucleoproteins (HNRNPs). Furthermore, when maintained under 
hypoxic conditions, these MYC-amplified tumors demonstrated increased viability 
compared to non-amplified tumors within the same subgroup. Taken together, these 
findings highlight the power of proteomics as an integrative platform to help prioritize 
genetic and molecular drivers of cancer biology and behavior.
INTRODUCTION
Remarkable progress has been made in defining the 
genomic aberrations that underlie pediatric brain tumors. 
In regard to medulloblastoma (MB), the most common 
malignant pediatric brain tumor, what was originally 
perceived to be a single entity is now known to consist of 
at least four distinct subgroups with significantly different 
clinical outcomes and therefore warranting individual 
therapeutic consideration [1]. Group 3 MB has the worst 
outcome with independent studies reporting between 
40 to 50% overall survival [1-3]. Metastases and myc 
amplification predict poor prognosis in Group 3 MB 
despite aggressive therapy [4]. As a result, there is an 
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imperative to improve therapy for patients with group 3 
tumors, with a particular focus on high risk cases [5].
Although transcript-based profiling technologies 
enable separation of subgroups based on gene expression, 
it is often difficult to interpret such signatures with respect 
to the biology of the disease. This is largely because 
these gene signatures do not incorporate important 
functions downstream of gene transcription, including 
splice isoform switching, selective translation and post-
translational modification [6]. Proteomics provides a 
unique complementary platform to precisely characterize 
altered signal transduction in cancer cells, examine cellular 
processes and identify potential therapeutic targets. Recent 
advances in mass spectrometry (MS) technology have 
improved protein identification and quantitation due to 
increased sensitivity, accuracy and speed of analysis [7-9]. 
The stable-isotope labeling of amino acids in cell culture 
(SILAC) method is a particularly accurate quantitative 
technique that has recently been used to identify diffuse 
large B-cell lymphoma subtypes and quantify diverse 
human tumor proteomes [6, 10]. 
SILAC involves incorporating amino acids 
constructed using the isotopes 13C and/or 15N into proteins. 
This increase in mass allows otherwise chemically 
indistinguishable peptides from different samples to 
be individually quantified by the mass spectrometer, 
even when pooled. Specifically, a protein lysate from 
an experimental sample can be pooled with a known 
quantity of an isotope-labeled protein lysate, fractionated 
and digested into peptides. The mass spectrometer 
can then quantitate both the naturally occurring 12C- 
and 14N-containing as well as the heavy analytes as a 
ratio. Performing this process iteratively with multiple 
experimental samples is a proven method for relative 
quantification of peptides, and thus proteins, between 
those samples [12].
We present here the first in depth proteomic 
profiling of MB using multiple SILAC labeled cell 
lines as an internal standard for agnostic tumor protein 
quantification. We specifically investigate proteins with 
differential abundance between low (non-MYC amplified) 
and high risk (MYC amplified) group 3 MB tumors [11], 
and identify targets that provide insight into the tumor 
biology of this aggressive subgroup. In summary, our data 
demonstrates the potential of SILAC-based proteomics 
to reliably quantify global proteome differences and 
to complement the current understanding of genomic 
abnormalities in medulloblastoma.
RESULTS
Super-SILAC proteomic analysis enables accurate 
quantification of subgroup specific proteins
Current antibody based proteomic techniques are 
useful tools, but only once a small set of target proteins 
have been identified. Mass spectrometry, by contrast, 
provides broad proteome coverage, but has historically 
been plagued by low sensitivity, inaccurate quantitation 
and technical variability. For this study, we utilized a 
novel SILAC based mass spectrometry technique to 
reproducibly quantify proteome differences in human 
primary tumor cells. The SILAC approach involves the 
use of a set of stable isotope-labeled labeled peptides 
that can be spiked, at known amounts, into test samples 
and used as an internal reference standard for accurate 
quantification of proteins by mass spectrometry [12]. We 
developed a unique SILAC reference standard comprised 
of three labeled MB tumor cell lines (DAOY, D556, 
D283) and a labeled low passage primary MB tumor cell 
culture (R026; group 3 non-metastatic tumor) (Figure 1A). 
This mixture is termed super-SILAC as it is a superset 
of SILAC cell lines and has previously been shown to 
achieve superior quantification accuracy compared to 
single SILAC-labeled cell line standards [10]. Creating 
the reference from a pool of labeled protein lysates from 
multiple MB primary and established cell lines broadens 
proteome coverage to increase the number of quantifiable 
proteins in the experimental MB samples.
To test the proteomic coverage and accuracy 
of our unique super-SILAC standard when studying 
heterogeneous subsets of MB, we evaluated primary 
lines representing the 4 molecular subgroups of MB. We 
identified between 1400-1900 proteins per primary MB 
cell line; ≥94.5% of all peptides fell within a 2.5-fold ratio 
of tumor to SILAC standard (Figure 1B). This narrow 
ratio distribution contributed to significantly higher 
quantification accuracy with all MB cells displaying 
a ≥0.92 Pearson correlation coefficient of variation 
between triplicate analyses (Figure 1B). Approximately 
half of all proteins identified (45-56%), using stringent 
peptide probability scores and false discovery rate filters 
(see Methods and materials), were shared by all MB 
subgroups, with Group 3 and Group 4 displaying the 
greatest similarity in their proteomes (Figure S1). There 
was no significant difference in quantification accuracy 
and proteome coverage across the MB subgroups ( > 80% 
of proteins overlapped between the standard and each 
sample; Figure S1), demonstrating the ability of our super-
SILAC standard to function across diverse subgroups of 
MB. In summary, our unique MB super-SILAC standard, 
together with high-resolution mass spectrometry, was 
able to accurately and reproducibly quantify a large 
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Figure 1: Effective quantification of human primary tumor cells using a super-SILAC reference standard. A. 
Experimental scheme of quantification analysis using mixed lysates of multiple MB tumor cell lines. Lysates of labeled cells (Lys-8, 13C
6
 
15N
2
-Lysine; Arg-10, 13C
6
 15N4-Arginine) are mixed with tumor lysate (at a 1:1 ratio) and analyzed by high resolution liquid chromatography-
MS/MS. B; Histograms of the ratios between the tumor protein and our super-SILAC reference, and a comparison of ratios (r = Pearson 
correlation coefficient) between replicates demonstrates the high quantification accuracy of our technique. Superior accuracy is achieved 
when quantified proteins (proportion indicated by percentage above histogram) lie within four-fold ratio between tumor and super-SILAC 
reference [10]
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set of proteins across all MB tumor subgroups. Having 
illustrated the effectiveness of our super-SILAC standard, 
we next evaluated the proteomic differences between 
MYC amplified versus non-amplified tumors.
Differential proteome patterns in MYC amplified 
versus non-MYC amplified Group 3 tumor cells
Group 3 MB has the worst overall survival ( < 50%) 
and transcriptional profiling analyses have not revealed 
actionable targets. MYC amplification in this subtype is 
significantly associated with metastasis and poor survival, 
yet little is known regarding the cellular and molecular 
mechanisms that produce this aggressive phenotype. 
Using our super-SILAC standard we explored the global 
proteome differences between human MYC amplified 
(MYC+, n = 3) versus non-MYC amplified (MYC-, n = 3) 
Group 3 primary tumor cells. Interestingly, unsupervised 
hierarchical clustering of the median protein expression 
values of all quantified proteins resulted in segregation 
by MYC amplification status (Figure 2A-2B). Focusing 
Figure 2: Differential proteome expression patterns between MYC-amplified versus non-amplified tumors. A. 
Unsupervised hierarchical clustering (normalized log
2
 and standardized to mean signal = 0 and standard deviation = 1) of protein expression 
profiles from six Group 3 primary MB cells B. Differential protein expression drives segregation of tumor cells with MYC-amplification, 
which is not seen when similar analysis is conducted using transcriptome data (see FigS3). B, C. Top up-regulated proteins and predicted 
functional pathways in MYC-amplified tumors. STRING-generated protein-protein interaction pathways revealed significant (P, 0.05; 
t-test) connectivity in alternative splicing, ribosome biogenesis and metabolism pathways. Error bars represent standard deviation between 
the cultures in each subgroup (n = 6)
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on only significant protein changes (p-value with FDR 
correction < 0.001), we identified 185 proteins (Table 
S1) that were differentially expressed between MYC 
amplified and non-amplified tumors (Figure 2C; Table S1). 
Intriguingly, some of the highest differentially expressed 
proteins, such as orthodenticle homeobox 2 (OTX2) and 
DEAH box helicase 9 (DHX9), have previously been 
shown in genomic studies to be strongly associated 
with Grp3/4 MB [1, 2, 12]. To determine the functional 
significance of these proteins, we utilized the Search 
Tool for the Retrieval of INteracting Genes/Proteins 
(STRING) database of physical and functional interactions 
[13]. In the global STRING-generated protein-protein 
network, several complexes and cellular functions formed 
prominent tightly connected clusters (Figure S2). Cellular 
processes such as RNA splicing and cellular metabolism 
Figure 3: Validation of differential protein expression in independent human MB tissue samples and evidence for 
increased alternative splicing of PKM. A. Confirmation of proteomic alterations in independent human MB tissue samples using 
western blot. Significant (t-test) alterations in splicing associated factors were conserved between low passage primary tumor cell cultures 
and human tissue samples. B. Quantitative real-time PCR in human MB tissue and cell cultures reveals increased alternative splicing of 
PKM to produce the pro-glycolytic PKM2 isoform in MYC amplified tumors. C. cDNA samples from independent human tissue samples 
were subjected to PCR amplification using primers amplifying a 442 bp exon 8-11 region common to PKM1 and PKM2. Following 
incubation with PstI, the uncleaved (PKM1, 442 bp) and cleaved (PKM2, 246 and 196 bp) amplification products were separated by 
electrophoresis and quantified, with total signal set at 100 for each lane (Lane 1 uncut MYC-, Lane 2 uncut MYC+). There is significantly 
higher splicing of mRNA which is indicative of higher PKM2 isoforms. 
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were particularly enriched in MYC+ tumors compared 
to MYC-. These MYC+ associated cellular pathways 
prominently featured heterogeneous ribonucleoproteins 
(HNRNPAB, HNRNPH1, and HNRNPC) and serine/
arginine-rich splicing factors (SRSF2, SRSF7), indicative 
of post-transcriptional modification pathways. We further 
validated our proteomic data by western blot analysis, 
confirming the significantly differential expression of 
spliceosome associated proteins (Figure S3). Western blot 
analysis of Grp3 tumor cell lines was consistent with our 
super-SILAC mass spectrometry observations.
To determine the relationship between our 
proteomic findings and the transcriptomic landscape, we 
performed an orthogonal analysis of independent gene 
expression data from the largest single human MB study 
(GEO accession number GSE37385) [14] to determine 
the differential gene expression between ten MYC+ and 
ten MYC- human Grp3 MB tumors. There was limited 
concordance between protein and mRNA variation (8% 
similarity with differentially expressed gene transcripts 
with p < 0.05). Interestingly, interaction pathways 
generated from these common proteogenomic targets 
revealed strikingly similar pathways to those seen in our 
proteomic data alone (Figure S3;. These results highlight 
the strength of proteomics to help validate and prioritize 
the broad output of genomic studies to determine those 
most closely associated with cancer function/biology.
Cross-validation of proteomic MYC-signature in 
independent human tumor tissue samples
Proteomic differences in our primary tumor cultures 
could result from adaptations to an in vitro culturing 
system and may not faithfully reflect protein expression 
in human tumor tissues. To validate proteomic differences 
shown in our super-SILAC system, we used western 
blotting on an independent group of human tumor tissue 
samples (n = 10; see Table S2). Greater proteomic 
variability was observed between human tumor tissue 
samples than in culture, however significant differences 
in HNRNPA2/B1 (p = 0.005) and MYC (p = 0.013) were 
still detected between MYC+ and MYC- tissues (Figure 
3A). There were no significant differences in HNRNPA1 
(p = 0.068) and HNRNPC (p = 0.281), which were 
significantly higher in MYC+ primary cultures compared 
to MYC-. These results support our in vitro finding of 
altered expression of splicing factors in MYC+ group 3 
human MB tissues.
We next determined whether this significant increase 
in splicing factors was associated with increased splicing 
of their targets. Notably, HNRPNPA1, HNRPNPA2 and 
PTB have previously been shown to regulate alternative 
splicing of pyruvate kinase pre-mRNA (PKM) resulting in 
increased levels of the embryonic pyruvate kinase isoform, 
PKM2 [15]. Importantly, PKM2 promotes aerobic 
glycolysis, whereas the adult isoform, PKM1, promotes 
oxidative phosphorylation. These two isoforms result 
from mutually exclusive alternative splicing of PKM pre-
mRNA leading to the inclusion of either exon 9 (PKM1) 
or exon 10 (PKM2). We therefore used quantitative PCR 
analysis using primers specific for PKM exon 9 or PKM 
exon 10 to determine shifts in the PKM2/PKM1 ratio. 
Real time PCR (RT-PCR) revealed increased levels of 
the PKM2 isoform in the MYC+ MB tumors compared to 
MYC- tumors, and a subsequently higher PKM2/PKM1 
ratio (Figure 3B). Although there was high variability in 
the PKM2/PKM1 ratios among the MYC+ tumor tissues, 
the mean ratio was significantly higher (P = 0.016, Mann-
Whitney test) than in the non-amplified MYC tumors. This 
was further confirmed in a partially overlapping human 
MB tumor tissue set using a restriction enzyme assay to 
assess the proportion of PKM1 and PKM2 (Figure 3C; P 
= 0.012, t test).
Alterations in glycolytic metabolism in MYC 
amplified MB tumor cells
Alternative splicing of PKM plays an important role 
in determining the metabolic phenotype of mammalian 
cells. We set out to determine if the increased splicing 
factors and subsequent alternative splicing of PKM, 
resulting in a high PKM2/PKM1 ratio, correlated with 
glycolytic metabolism in these tumor cells. Intriguingly, 
MYC amplified tumor cells displayed a significantly 
higher production of total oxidized and reduced 
nicotinamide adenine dinucleotide phosphates (NADP+ 
and NADPH, respectively) when compared to non-
amplified (MYC-) cells (P < 0.01; Figure 4A). High 
metabolic flux through glycolysis produces ATP and 
intermediates which subsequently generate NADPH and 
ribose for reductive biosynthetic reactions and nucleotide 
synthesis - both critical to a highly proliferative phenotype. 
Surprisingly, although increased reactive oxidative species 
(ROS) production is associated with up-regulation of 
glycolysis, we saw significantly lower levels of H
2
0
2
 in our 
MYC-amplified tumor cells (P < 0.01; Figure 4A). This 
ROS quantification was independent of cell survival and 
proliferation, as determined by cell viability assays after 
ROS measurements (Figure S4). As we also demonstrate 
significantly higher protein expression of superoxide 
dismutase (SODm) in MYC+ tumors (see Table S1), these 
results may suggest an adaptation to a phenotype resistant 
to acid-induced toxicity. Constitutive up-regulation of 
glycolysis is proposed to be an adaptation to hypoxia. To 
test this, we compared ATP production in cultures grown 
under hypoxic ( < 1% O
2
) and normoxic conditions. All 
non-amplified MYC cultures, except for the DAOY cell 
line, produced significantly (P < 0.05) lower ATP when 
grown in hypoxic conditions (Figure 4B). Conversely, 
there were no significant differences in ATP production in 
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MYC+ cells grown in a hypoxic environment, except for 
the D556 cell line, when compared to normoxia (Figure 
4B). In summary, energy production was unperturbed 
in primary MYC+ MBs when cultured under hypoxic 
conditions.
Figure 4: MYC-amplified tumor cells have significantly altered metabolic activity compared to the rest of Group 3 MB 
cells (non-MYC amplified). A. Although MYC amplified tumor cells have significantly lower reactive oxidative species (H
2
O
2
), they 
also have higher levels of total nicotinamide adenine dinucleotide phosphates (t-test; p < 0.01; error bars are standard deviation between 
subgroup cultures). B. ATP production under hypoxic conditions (48 hours, 0.1% O
2
) is significantly reduced in most (3/4) non-MYC 
amplified tumor cells, but is not perturbed in MYC-amplified tumors (3/4). Error bars are standard deviation of sample replicates; t-test,* 
denotes P < 0.05.
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DISCUSSION
The results of this study demonstrate the power 
of quantitative proteomics as a platform to help discern 
molecular and genetic drivers of cancer. The application of 
proteomics is particularly useful when studying genetically 
ambiguous tumors like group 3 MB, which has the highest 
levels of recurrence and the worst overall survival rates 
[1, 3, 12]. Our proteomic findings, validated in clinical 
samples at the level of transcript and protein, provide new 
evidence of the biological effect of MYC amplification 
in group 3 MB. Specifically, we demonstrate alternative 
splicing of pyruvate kinase mRNA by HNRNPs and the 
subsequent altered metabolic phenotype in these tumors. 
Intriguingly, this may influence the bioenergetics of MYC 
amplified tumors and therefore confer a powerful growth 
advantage necessary for the evolution and metastasis of 
this aggressive cancer.
Our proteomics data highlight significant differences 
in the metabolism of MYC amplified versus non-amplified 
tumors. This pathway has not previously been studied in 
MB, possibly due to the hypothesis that MYC amplification 
was primarily associated with dysregulated cellular 
proliferation with a subsequent increase in metabolism. 
However, previous findings that MYC directly regulates 
genes involved in glucose metabolism and ribosome 
biogenesis (also supported in this study), suggests that the 
increased production of metabolic enzymes in growing 
cells is far from a passive phenomenon [16-19]. Enhanced 
metabolic capacity is essential for biomass accumulation 
and high-fidelity DNA replication in a growing cell. This 
enhanced capacity requires rewiring of the metabolic 
energetics of a resting cell into that of a growing and 
proliferating cell. To this effect, MYC stimulates virtually 
all of the genes involved in glycolysis [15, 20]. High 
metabolic flux through glycolysis provides growing cells 
with the building blocks for macromolecular synthesis 
and ATP production. Importantly, our results suggest that 
this shift in metabolism in MYC amplified tumors may 
likely influence the adaptation of these cells to a hypoxic 
microenvironment. This is supported by evidence that 
MYC induction of glutamine metabolism is important 
for cell survival under glucose and oxygen-deprived 
conditions [18, 20]. Taken together, we propose that this 
MYC-amplification associated glycolytic phenotype may 
confer a powerful growth advantage and influence the 
aggressive behavior of this tumor subtype.
It is important to note that myc amplification in 
this context defines a subgroup of tumors whose biology 
is not necessarily wholly defined by the transcriptional 
activity of MYC and its target genes. This is an important 
distinction that has been written about previously [21]. 
In fact, increased MYC expression (without MYC copy 
number variation) is also found in the WNT subgroup 
medulloblastoma tumors with the highest survival. The 
data presented here support the concept that there are 
significant differences in protein expression between 
MYC-amplified and non-amplified tumors, though 
whether this is directly related to increased MYC 
transcript expression is an open question. For example, 
two of the primary MYC amplified lines used to generate 
the proteomic data also harbor OTX2 amplifications. As 
OTX2 amplification is known to cooperate with MYC 
to amplify its transcriptional program, and OTX2 was 
the most differentially expressed protein found in the 
MYC+ group, it is possible that the proteomic phenotype 
here described is driven by the cooperation of these two 
oncogenes [22].
MYC amplification is more closely associated with 
group 3 MBs than any other group and makes an excellent 
prognostic marker in combination with established clinical 
risk factors [11]. However, transcriptional profiling 
has not revealed appreciable myc-dependent signaling 
pathways [2, 12] and next-generation sequencing in three 
independent studies yielded few recurrent mutations in this 
group [3, 23-25]. The proteomics perspective enhances 
and complements our current understanding of genomic 
drivers of cancer biology and provides a novel platform 
for exploring molecular pathways in medulloblastoma.
MATERIALS AND METHODS
Patients and samples
The use of human tissue (Table S2) was approved 
by the institutional review board of Children’s National 
Medical Center (Washington DC, USA) (IRB 4932). 
Written informed consent was obtained at the time of 
surgical resection. De-identified MB tissue were obtained 
from Queensland Children’s Tumor Bank (Brisbane, 
Australia), German Cancer Research Center (Heidleberg , 
Germany), Sanford-Burnham Medical Research Institute 
(La Jolla, USA), and Hospital for Sick Children (Toronto, 
Canada). Primary passage patient derived mouse xenograft 
cells were provided by Dr. Wechsler-Reya (Sanford-
Burnham Medical Research Institute, La Jolla, USA).
Cell lines and SILAC culture
Primary MB cell cultures R001, R026, R032, R060, 
and R066 (see Table S2 for details) were obtained from 
Queensland Children’s Tumor Bank. The cell lines were 
cultured in ‘light’ DMEM: F12 media (Gibco) containing 
naturally occurring lysine and arginine and supplemented 
with 10% fetal bovine serum (Gibco), 1% glutamax 
(Gibco), 1% sodium pyruvate (Life Technologies, Grand 
Island, NY) and 1% penicillin/streptomycin/fungizone 
(supplier). MB002 and MB004 cell cultures were a kind 
gift from Dr. Jae Cho (Stanford University, Stanford, 
CA) and maintained in 1:1 DMEM/F12 (Gibco) and 
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Neurobasal-A medium (Gibco) supplemented with 
B27 (Gibco), EGF (Fisher Scientific), fibroblast growth 
factor (Fisher Scientific), Heparin (Sigma-Aldrich), and 
leukemia inhibitory factor (Millipore). Established MB 
cell lines D556 and D283 were generously provided by 
Dr. Darrell Bigner (Duke University, Durham, NC) and 
the DAOY cell line obtained from the American Type 
Tissue Collection. These cell lines were SILAC-labeled 
by culturing in DMEM media (Life Technologies, 
Grand Island, NY) containing ‘heavy’ isotope-labeled 
essential amino acids, 13C
6
 ,15N
2
-lysine (Lys-8) and 
13C
6
, 15N4-arginine (Arg-10 ). The labeled amino acids 
were purchased from Cambridge isotope Laboratories 
(Andover, MA). Media was supplemented with 10% fetal 
bovine serum, 1% glutamax, 1% sodium pyruvate and 
1% antibiotics as above. The primary cell line R026 was 
also SILAC labeled by culturing in DMEM:F12 media 
(Thermoscientific, Rockford, IL) where Lys-8 and Arg-
10 replaced naturally occurring amino acids. Cell lines 
were cultured for at least 6 population doublings until 
fully labeled, as confirmed by mass spectrometry ( > 
99% incorporation, data not shown). All cell lines were 
maintained at 37°C and 5% CO
2
. It is important to note 
that of the cell lines used in our super-SILAC mix, D283 
and D556 harbor cMYC gene copy number amplifications 
whereas DAOY and R026 do not.
Cell pellets from all unlabeled cell lines and SILAC-
labeled cell lines and snap frozen tumor tissue were lysed 
in RIPA buffer (Millipore, Temecula, CA) containing 
2% SDS (Lonza, Rockland, ME) and protease inhibitors 
(Thermoscientific, Rockford, IL). Lysates were incubated 
on a shaker at 4°C for 30 minutes and sonicated for 10 
minutes followed by centrifugation. Snap frozen tumor 
tissue was homogenized with a handheld homogenizer 
then lysed using the same method. The supernatant was 
reserved and protein concentration was determined by 
BCA assay (Pierce Thermoscientific, Rockford, IL) at a 
wavelength of 562nm. The super-SILAC spike-in standard 
was created by mixing equal amounts of protein from 
each SILAC-labeled cell line (R026, DAOY, D556 and 
D283). Protein concentration was determined by BCA 
assay and aliquots of the standard were stored at -80°C 
until required. 
Super-SILAC standard and proteomics
Unlabeled primary cell lysates were mixed with the 
super-SILAC standard in a 1:1 ratio by protein content, as 
determined by BCA assay. All samples were desalted and 
buffer exchanged to Tris/HCl buffer using Micro bio-spin 
6 columns (Bio-Rad, Hercules, CA). Protein concentration 
was determined by BCA assay and aliquots containing 
80ug of total protein per sample run (up to 240ug for 
triplicate analysis) were dried by vacuum centrifugation. 
Protein pellets were resuspended in XT sample buffer 
containing Criterion XT reducing agent and denatured at 
95°C for five minutes. Proteins were resolved by SDS-
PAGE on Criterion XT 4-12% Bis-Tris gels (Bio-Rad, 
Hercules, CA) at 180 volts for 1 hour. The gels were 
fixed (50:5:45/methanol:aceticacid:water/v:v:v), stained 
with Bio-Safe Coomassie blue (Bio-Rad, Hercules, CA) 
and destained in H2O. 32 gel sections were excised from 
each sample run and the individual bands were processed 
for in-gel trypsin proteolysis as previously described10. 
Trypsin digestion was performed using 12.5ng/ul of mass 
spectrometry grade Trypsin (Promega, Madison, WI) 
diluted in 25mM NH4HCO3 solution. Peptides recovered 
from each band were dried by vacuum centrifugation and 
resuspended in 8ul of 0.1% TFA for mass spectrometry 
analysis.
Mass spectrometry analysis
NanoLC MS and MS/MS were conducted using 
the Eksigent nanoLC 2D HPLC system (Eksigent 
Technologies, Inc., Dublin, CA) coupled to the LTQ-
Orbitrap XL hybrid mass spectrometer (Thermo Fisher 
Scientific, San Jose, CA). Peptides from each band were 
injected via an autosampler (6uL) and loaded onto a 
Symmetry C18 trap column (5µm, 300 µm i.d. x 23 mm, 
Waters) for 10 min at a flow rate of 10 µL/min, water with 
0.1% formic acid. The sample was subsequently separated 
by a C18 reverse-phase column (3 m, 200A, 100 µm x 15 
cm, Magic C18, Michrom Bioresources) at a flow rate of 
300 nL/min using an Eksigent nano-hplc system (Dublin, 
CA). The mobile phases consisted of water with 0.1% 
formic acid (A) and 90% acetonitrile (B). A 65 minute 
linear gradient from 5 to 60% B was employed. Eluted 
peptides were introduced into the mass spectrometer via 
Michrom Bioresources CaptiveSpray. The spray voltage 
was set at 2.2kV and the heated capillary at 200°C. The 
LTQ-Orbitrap-XL (ThermoFisherScientific) was operated 
in data-dependent mode with dynamic exclusion in which 
one cycle of experiments consisted of a full-MS in the 
Orbitrap (300-2000 m/z) survey scan in profile mode, 
resolution 30,000, and five subsequent MS/MS scans 
in the LTQ of the most intense peaks in centroid mode 
using collision-induced dissociation with the collision gas 
(helium) and normalized collision energy value set at 35%. 
Proteins were identified and quantified from spectral data 
using Integrated Proteomics Pipeline (IP2) version 1.01 
software developed by Integrated Proteomics Applications, 
Inc. (http://www.integratedproteomics.com/). Files from 
each sample lane were searched against the forward and 
reverse Uniprot human database (UniProt release 2013_01 
with 20,226 reviewed entries) for partially tryptic peptides 
allowing one missed cleavage, and possible modification 
of oxidized methionine (15.99492 Da) and heavy arginine 
(6.0201 Da) and heavy lysine (8.0142 Da). IP2 uses the 
Sequest 2010 (06_10_13_1836) search engine. Mass 
tolerances were set at +/- 50 ppm for MS and +/- 1.5 Da 
for MS/MS. Data were filtered based on a 1% protein 
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false discovery rate and two unique peptides. All the 
bands from each lane were \summed in the analysis. 
Census software version 1.77, built into the IP2 platform, 
was used to determine the ratios of unlabeled and labeled 
peptide pairs using an extracted chromatogram approach. 
The distribution of ratios was plotted and correction 
factors applied to adjust for error in sample mixing. Data 
were checked for validity by using regression correlation 
better than 0.5 for each peptide pair. Peptide ratios were 
averaged to yield the protein ratio with standard deviation.
Western blot
Protein lysates from MB primary cultures and frozen 
operative tissue were prepared in lysis buffer (50 mM 
HEPES, pH7.0, 150 mM NaCl, 2% SDS, 1 mM EDTA) 
supplemented with protease and phosphatase inhibitors 
(Roche). Proteins were separated on 4–20% Bis-Tris 
gradient polyacrylamide gels (Invitrogen) and transferred 
onto Immuno-Blot nitrocellulose membranes (Bio-
Rad Laboratories). Membranes were then incubated in 
blocking buffer (1X TBS containing 5% milk and 0.05% 
Tween-20, 1 hour), probed overnight with antibodies 
specific for HNRNPA2/B1 (Cell Signaling, 1:1000), 
HNRNPA1 (4B10; Santa Cruz; 1:2000), HNRNPC1/C2 
(4F4; Santa Cruz; 1:5000), cMYC (9E10; Santa Cruz; 
1:500) and actin (Sigma; 1:2000).
Quantitative RT-PCR
Total RNA was isolated from samples 
(Qiagen RNeasy Kit), treated with DNase I, reverse 
transcribed (Superscript II Reverse Transcriptase 
Kit, Invitrogen) and amplified (initial denaturing 
of 95˚C for 3 min followed by 40 cycles at 95˚C 
for 15 sec, 60˚C for 15 sec, and 72˚C for 30 sec) in 
triplicate using primers designed to bind to PKM1-
specific exon 9 (F-ACCGCAAGCTGTTTGAAGAA 
and R-TCCATGAGGTCTGTGGAGTG) or PKM2-
specific exon 10 (F-GAGGCCTCCTTCAAGTGCT 
and R-CCAGACTTGGTGAGGACGAT), sequences, 
respectively as previously described [26]. The mean Ct 
values for each set of amplifications were determined, 
after which the mean Ct value from triplicate qPCR 
reactions using primers for the housekeeping gene Actin 
were subtracted to derive a ΔCt value. Relative mRNA 
expression was expressed as 2ΔCt.
PKM splicing assay
The PKM splicing assay used was conducted as 
previously described [15, 26]. Briefly, RNA isolated from 
normal or tumor samples (fixed or frozen) was reverse 
transcribed then amplified (98 ˚C for 3 min followed 
by 98˚C for 20 sec, 65˚C for 20 sec, 72˚C for 30 sec for 
34 cycles) using a forward primer that bound to shared 
PKM1/2 exon 8 and a reverse primer that bound to 
shared PKM1/2 exon 11 sequences [15]. The 442 bp PCR 
products representing both PKM1 and PKM2 transcripts 
were then digested with PstI and electrophoresed, after 
which the 442 bp (uncut PKM1-specific amplicon) and 
246 bp and 196 bp (PstI-cleaved PKM2-specific amplicon) 
products were quantitated (Image-J software). Sham-
digested PCR products were used as a control for the PCR 
amplification while PstI-digested amplification products 
derived using a PKM2 cDNA template were used as a 
control for restriction enzyme digestion.
Network analysis for protein-protein interactions
The Uniprot identifiers of our highly increased 
proteins in MYC-amplified tumors (3-fold and higher; 
p-value with FDR correction < 0.01) were mapped to the 
Ensemble protein identifiers, and then searched against 
the STRING database version 9.1 [13] for protein-protein 
interactions. Only interactions between the proteins 
belonging to our MYC-amplification dataset were selected. 
STRING defines a metric called “confidence score” to 
define interaction confidence; we fetched all interactions 
for our acetylation dataset which had a confidence score ≥ 
0.7 (high confidence).
Genome-wide expression analysis
Previously published microarray expression 
and copy-number data3 were obtained from the Gene 
Expression Omnibus (GEO; GSE37385 and GSE37382). 
The expression data were obtained using the GEOImporter 
module in GenePattern. Z scores of gene expression values 
of genes within samples were calculated. The genes were 
mapped to ensemble identifiers and searched against the 
STRING database version 9.1 [13] to identify enriched 
interactions.
Oxygen deprivation
Tumor cells were seeded in triplicate in 24 well 
plates (Corning Costar, Sigma Aldrich, St. Louis, MO) in 
appropriate medium (blank wells contained only media 
without cells). The normoxia set of plates were placed 
in an aerobic incubator (atmospheric) and the hypoxic/
anoxic set were placed in a ProOx110/ProCo
2
/C-Chamber 
(Biospherix, Japan), which was equilibrated to 37˚C in 
a humidified atmosphere of 5% CO
2
 and 0.1% O
2 
. At 
the appropriate time, the cells were removed from the 
incubator and equal volumes of CellTiter-Glo® (Promega, 
Madison, WI) added to each culture and mixed for 2 min 
at room temperature as described per protocol. After 
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allowing 10 min to stabilize the luminescent signal, 200µl 
of each of the lysates (including replicates) were placed 
in opaque-walled 96-well plates and the luminescence 
recorded (FLUOstar optima, BMG labtech, Ortenberg, 
Germany).
Metabolite measurements
The NADP/NADPH-GloTM assay (Promega, 
Madison, WI) was used to detect total oxidized and 
reduced nicotinamide adenine dinucleotide phosphates. 
The ROS-GloTM H
2
O
2
 assay (Promega, Madison, WI) was 
used to measure the level of hydrogen peroxide (H
2
O
2
) 
in culture. All assays were performed as directed in the 
protocol. Briefly, for NADP/NADPH measurements, 
tumor cells were seeded at the same concentration (104 
per well) in triplicate in 24 well plates for 6 hours prior to 
the addition of an equal volume of the NADP/NADPH-
Glo TM detection reagent to each well. The luminescence 
is read after incubation with the detection reagent for 60 
min at room temperature. For H
2
O
2 
measurements, tumor 
cells were seeded at the same concentration (104 per 
well) in triplicate in 24 well plates for 24 hours (aerobic 
incubator). 25µM of the H
2
O
2
 substrate was added for the 
last 6 hours of incubation and 50µl of media samples per 
well were removed and mixed with detection solution 
(50µl). Luminescence was measured after incubation with 
the detection solution for 20 minutes at room temperature.
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